News

FDA Approves Nucala for Chronic Obstructive Pulmonary Disease
By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
US Approves GSK Lung Disease Drug, Fueling Sanofi Rivalry
GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.
GSK's asthma drug wins FDA approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
MedPage Today5h
FDA Approves Mepolizumab for COPD
Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
Healio11h
Mepolizumab lowers severe exacerbation risk in COPD, type 2 inflammation at 104 weeks
Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...
Rethinking COPD diagnosis to improve accuracy and early detection
University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...
HealthDay on MSN1d
Persistent, New Mucus Plugs Associated With Faster Decline in FEV1 in COPD
For patients with chronic obstructive pulmonary disease (COPD), persistent and newly formed mucus plugs are associated with a ...
Pulmonology Advisor3d
Women and Lung Disease: Sex-Specific Patterns in COPD, Asthma, and OSA
Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...
PharmExec7h
FDA Approves GSK’s Nucala for Chronic Obstructive Pulmonary Disease
Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.